Medication info
Dapagliflozin Met Extended-Release Tablet 5/500 mg

Dapagliflozin Met Extended-Release Tablet 5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›7.35mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
Dong-Gu Bio Pharmaceutical Co., Ltd.
Appearance
Orange, biconvex, oval film-coated tablet.
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202204356 · Approved 2022.12.05 · Insurance code 657308840

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
Dong-Gu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood glucose control disorders
  • cardiovascular diseases
  • cardiovascular risk factors.
View approved original text

This medication is used to improve blood glucose control in adult patients with type 2 diabetes when dapagliflozin and metformin are administered together. It is used as an adjunct to dietary and exercise therapy, particularly in patients who do not have sufficient blood glucose control. In addition, the effects of dapagliflozin on the occurrence of cardiovascular events should be carefully monitored in type 2 diabetes patients with cardiovascular disease or risk factors. Please consult professional information before use to ensure safe usage. This medication effectively improves blood glucose control in diabetic patients.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication is used for diabetes treatment and contains metformin and dapagliflozin. This medication should not be used in patients with poor kidney function or certain heart diseases and liver dysfunction. Before administration, kidney function and fluid status must be confirmed, and caution is especially needed in elderly patients or those with dehydration. Hypoglycemic symptoms may occur during treatment; therefore, dosage adjustments may be necessary when taken with insulin or other blood glucose-lowering agents. Lactic acidosis, a rare side effect, can be life-threatening, so if symptoms such as fatigue, muscle pain, or shortness of breath occur, immediate consultation with medical personnel is required. The risk of genital and urinary tract infections may increase, so prompt treatment should be sought if infection symptoms arise. Pregnant or breastfeeding women should not use this medication; if planning to become pregnant, consult a physician. The risk of side effects may increase when taking this medication with alcohol, so excessive drinking should be avoided. In cases of overdose, immediate medical attention is necessary; dialysis may be required. The safety and efficacy of this medication in children have not been established, so it should not be used in children. Regular monitoring of kidney function and serum vitamin B12 levels is recommended during treatment. Caution is required when driving or operating machinery as dizziness may occur.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant lung neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • fibromyalgia syndrome
  • osteoarthritis
  • osteochondritis
  • limb pain
  • periarticular inflammation
  • tendinosis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain storage temperature between 1 degree and 30 degrees Celsius to safely preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Orange, biconvex, oval film-coated tablet.

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.